Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335153 · ClinicalTrials.gov registry record · Phase 3
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
A Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
NCT00335153: Completed Phase 3 study, sponsored by AbbVie (prior sponsor, Abbott).
NCT00335153 is a Phase 3 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 354 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00335153, a Phase 3 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
Study Summary
The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.
Primary Outcome
AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emerg
Interventions
- DEVICE CADD-Legacy® 1400 ambulatory infusion pump
- DRUG Levodopa-carbidopa intestinal gel
- DEVICE PEG tube
- DEVICE J-tube
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
What the finished NCT00335153 record still lists
NCT00335153 is an interventional study that assigns participants to a tested intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 4 interventions - of which CADD-Legacy® 1400 ambulatory infusion pump is the first listed.
NCT00335153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00335153 about?
NCT00335153 is a clinical study titled "Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease". The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.
What is the current status of trial NCT00335153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2008-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00335153?
The interventions under investigation include: CADD-Legacy® 1400 ambulatory infusion pump (DEVICE), Levodopa-carbidopa intestinal gel (DRUG), PEG tube (DEVICE), J-tube (DEVICE).
Who is sponsoring clinical trial NCT00335153?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00335153's enrollment target sits among peer trials
354 1026th of 2000 higher than 973 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia